A phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma

Cancer

Volumn 83, Issue 11, 1998, Pages 2317-2323

  Brembeck, Felix H ^a   Schoppmeyer, Klaus ^b   Leupold, Ursula ^b   Gornistu, Costel ^a   Keim, Volker ^b   Mössner, Joachim ^b   Riecken, Ernst Otto ^a   Rosewicz, Stefan ^a,c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Clinical trial; Interfetch ; Pancreatic carcinoma; Retinoic acid

Indexed keywords

ALPHA INTERFERON; ISOTRETINOIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INTERFERON-ALPHA; ISOTRETINOIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PILOT PROJECTS; SURVIVAL RATE;

EID: 0032400789     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO;2-P     Document Type: Article

References (31)

1. Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA Cancer J Clin 1990;40:9-26.
2. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995;82: 111-5.
3. Bakkevold KE, Arnesjo B, Kambestad B. Carcinoma of the pancreas and papilla of Vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Norwegian Pancreatic Cancer Trial. Scand J Gastroenterol 1992;27:317-25.
4. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;349:485-9.
5. Arbuck SG. Chemotherapy for pancreatic cancer. Baillieres Clin Gastroenterol 1990;4:953-68.
6. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995:31A:882-7.
7. Lotan R. Effects of vitamin A and its analog (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 1980;605: 33-91.
8. Bollag W. Vitamin A and retinoids: from nutrition to pharmacotherapy in dermatology and oncology. Lancet 1983;1: 860-3.
9. Lotan R, Lotan D, Sacks PG. Inhibition of tumor cell growth by retinoids. Methods Enzymol 1990;190:100-10.
10. Love JM, Gudas LJ. Vitamin A, differentiation and cancer. Curr Opin Cell Biol 1994;6:825-31.
11. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol 1992;3:513-26.
12. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992;10:839-64.
13. Tallman MS, Weirnik PH. Retinoids in cancer treatment. J Clin Pharmacol 1992;32:868-88.
14. Rosewicz S, Stier U, Brembeck F, Kaiser A, Papadimitriou CA, Berdel WE, et al. Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology 1995;109:1646-60.
15. Rosewicz S, Wollbergs K, v.Lampe B, Matthes H, Kaiser A, Riecken EO. Retinoids inhibit adhesion to laminin in human pancreatic carcinoma cells via the alpha6 betal-integrin receptor. Gastroenterology 1997;112:532-42.
16. Xu XC, Stier U, Rosewicz S, El-Naggar AK, Lotan R. Selective suppression of nuclear retinoic acid receptor beta gene expression in human pancreatic carcinomas. Int J Oncol 1996; 8:445-51.
17. Bollag W, Majewski S, Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia 1994;8:1453-7.
18. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235-41.
19. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-5.
20. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1993;85:499-500.
21. Moore DM, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol 1994;31(Suppl 5):31-7.
22. Eisenhauer EA, Lippman SM, Kavanagh JJ, Parades-Espinoza M, Arnold A, Hong WK, et al. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia 1994;8:1622-5.
23. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13: 1950-7.
24. Rosewicz S, Weder M, Kaiser A, Riecken EO. Antiproliferative effects of interferon alpha on human pancreatic carcinoma cell lines are associated with differential regulation of protein kinase C isoenzymes. Gut 1996;39:255-61.
25. Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG. Regional chemotherapy in advanced pancreatic carcinoma. Med Klin 1995;90:501-5.
26. Rosewicz S, Brembeck F, Kaiser A, Marshall ZV, Riecken EO. Differential growth regulation by all-trans retinoic acid is determined by protein kinase C alpha in human pancreatic carcinoma cells. Endocrinology 1996;137:3340-7.
27. Mallinson CN, Rake MO, Cocking JB, Fox CA, Cwynarski MT, Diffey BL, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ 1980;281:1589-91.
28. Friedman MA, Cassidy MJ, Hannigan JF, Gribble M, Torti FM, Reynolds RD. A phase III study of adriamycin + 5FU vs. BCNU + adriamycin + ftorafur for patients with advanced pancreatic cancer. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 1981;22:156.
29. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061-7.
30. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-5.
31. Moore M, Andersen J, Burris H. A randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer. J Clin Oncol 1997;15:2403-8.